1887
Research article Open Access
Like 1

Abstract

Introduction

Expanding access to HIV antiretroviral treatment is expected to decrease HIV incidence and acquired immunodeficiency syndrome (AIDS) mortality. However, this may also result in increased HIV drug resistance (DR). Better monitoring and surveillance of HIV DR is required to inform treatment regimens and maintain the long term effectiveness of antiretroviral drugs. As there is currently no formal European Union (EU)-wide collection of HIV DR data, this study aimed to assess the current HIV molecular surveillance capacity in EU/European Economic Area (EEA) countries in order to inform the planning of HIV DR monitoring at EU level. Thirty EU/EEA countries were invited to participate in a survey on HIV molecular surveillance capacity, which also included laboratory aspects. Among 21 responding countries, 13 reported using HIV sequence data (subtype and/or DR) for surveillance purposes at national level. Of those, nine stated that clinical, epidemiological and sequence data were routinely linked for analysis. : We identified similarities between existing HIV molecular surveillance systems, but also found important challenges including human resources, data ownership and legal issues that would need to be addressed.Information on capacities should allow better planning of the phased introduction of HIV DR surveillance at EU/EEA level.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2017.22.49.17-00269
2017-12-07
2017-12-11
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2017.22.49.17-00269
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/22/49/eurosurv-22-49-5.html?itemId=/content/10.2807/1560-7917.ES.2017.22.49.17-00269&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO; 2016. Available from: http://www.who.int/hiv/pub/arv/arv-2016/en/
  2. UNAIDS. 90-90-90 An ambitious treatment target to help end the AIDS epidemic. Geneva: UNAIDS; 2014.
  3. UNAIDS. Global AIDS update 2016. Geneva: UNAIDS; 2016.
  4. UNAIDS. Oral pre-exposure prophylaxis: putting a new choice in context. Geneva: UNAIDS; 2015.
  5. Gupta RK, Jordan MR, Sultan BJ, Hill A, Davis DHJ, Gregson J, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet. 2012;380(9849):1250-8.  https://doi.org/10.1016/S0140-6736(12)61038-1  PMID: 22828485 
  6. Spira S, Wainberg MA, Loemba H, Turner D, Brenner BG. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother. 2003;51(2):229-40.  https://doi.org/10.1093/jac/dkg079  PMID: 12562686 
  7. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcriptase. Science. 1988;242(4882):1168-71.  https://doi.org/10.1126/science.2460924  PMID: 2460924 
  8. Bebenek K, Abbotts J, Roberts JD, Wilson SH, Kunkel TA. Specificity and mechanism of error-prone replication by human immunodeficiency virus-1 reverse transcriptase. J Biol Chem. 1989;264(28):16948-56. PMID: 2476448 
  9. Clutter DS, Jordan MR, Bertagnolio S, Shafer RW. HIV-1 drug resistance and resistance testing. Infect Genet Evol. 2016;46:292-307.  https://doi.org/10.1016/j.meegid.2016.08.031  PMID: 27587334 
  10. World Health Organization (WHO). Global Action Plan on HIV Drug Resistance 2017-2021. Geneva: WHO; 2017. Available from: http://apps.who.int/iris/bitstream/10665/255883/1/9789241512848-eng.pdf?ua=1
  11. Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, et al. Impact of HIV Drug Resistance on HIV/AIDS-Associated Mortality, New Infections, and Antiretroviral Therapy Program Costs in Sub-Saharan Africa. J Infect Dis. 2017;215(9):1362-5.  https://doi.org/10.1093/infdis/jix089  PMID: 28329236 
  12. World Health Organization (WHO). HIV drug resistance surveillance guidance: 2015 update. Geneva: WHO; 2015. Available from: apps.who.int/iris/bitstream/10665/204471/1/9789241510097_eng.pdf?ua=1.
  13. Frentz D, Van de Vijver DAMC, Abecasis AB, Albert J, Hamouda O, Jørgensen LB, et al. Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe. BMC Infect Dis. 2014;14(1):407.  https://doi.org/10.1186/1471-2334-14-407  PMID: 25047543 
  14. Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, et al. Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe. Clin Infect Dis. 2016;62(5):655-63.  https://doi.org/10.1093/cid/civ963  PMID: 26620652 
  15. Sista P, Rinehart A, Wasikowski B, Winters B, Pattery T, Bacheler L. Nine-year trends in clinically relevant reduced susceptibility of HIV-1 to antiretrovirals. J Clin Virol. 2009;44(3):190-4.  https://doi.org/10.1016/j.jcv.2008.12.005  PMID: 19168389 
  16. European Centre for Disease Prevention and Control (ECDC). The 2016 ECDC roadmap for integration of molecular and genomic typing into European level surveillance and epidemic preparedness Version 2.1, 2016-19. Stockholm: ECDC; 2016.
  17. Shafer RW, Dupnik K, Winters MA, Eshleman SH. A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies. HIV Seq Compend. 2001;2001:1-51. PMID: 22324021 
  18. EUsurvey. Available from: https://ec.europa.eu/eusurvey/
  19. European Centre for Disease Control and Prevention (ECDC). ECDC Map Maker (EMMa). Stockhom: ECDC. [Accessed 27 Jul 2017]. Available from: https://emma.ecdc.europa.eu/
  20. European Centre for Disease Prevention and Control (ECDC) /World Health Organization Regional Office for Europe. HIV/AIDS surveillance in Europe in 2015; 2016.
  21. Centers for Disease Control and Prevention (CDC). Technical Guidance for HIV surveillance programs: Molecular HIV Surveillance (MHS). Atlanta: CDC; 2012. Available from: https://www.vdh.virginia.gov/epidemiology/DiseasePrevention/Programs/HIV-AIDS/SurveillanceProgram/documents/pdf/Final Att-4d MHS Tech Guidance.pdf
  22. SPREAD programme. Transmission of drug-resistant HIV-1 in Europe remains limited to single classes. AIDS. 2008;22(5):625-35.  https://doi.org/10.1097/QAD.0b013e3282f5e062  PMID: 18317004 
  23. Rhee S-Y, Blanco JL, Jordan MR, Taylor J, Lemey P, Varghese V, et al. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis. PLoS Med. 2015;12(4):e1001810.  https://doi.org/10.1371/journal.pmed.1001810  PMID: 25849352 
  24. Health Service Executive (HSE). HIV in Ireland - 2015 report. Dublin: HSE; 2016.
  25. Chaix M-L, Descamps D, Wirden M, Bocket L, Delaugerre C, Tamalet C, et al. Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France. AIDS. 2009;23(6):717-24. PMID: 19279445 
  26. Institut scientifique de Santé publique. Epidémiologie du SIDA et de l’infection à VIH en Belgique. Brussels; 2014.
  27. Yang W-L, Kouyos R, Scherrer AU, Böni J, Shah C, Yerly S, et al. Assessing the Paradox Between Transmitted and Acquired HIV Type 1 Drug Resistance Mutations in the Swiss HIV Cohort Study From 1998 to 2012. J Infect Dis. 2015;212(1):28-38.  https://doi.org/10.1093/infdis/jiv012  PMID: 25576600 
  28. Bezemer D, Cori A, Ratmann O, van Sighem A, Hermanides HS, Dutilh BE, et al. ATHENA observational cohort. Dispersion of the HIV-1 Epidemic in Men Who Have Sex with Men in the Netherlands: A Combined Mathematical Model and Phylogenetic Analysis. PLoS Med. 2015;12(11):e1001898, discussion e1001898.  https://doi.org/10.1371/journal.pmed.1001898  PMID: 26529093 
  29. Kirby Insitute. HIV in Australia Annual Surveillance Report 2014 Supplement. Sydney; 2014. Available from: https://kirby.unsw.edu.au/sites/default/files/hiv/resources/HIVASRsuppl2014_online.pdf
/content/10.2807/1560-7917.ES.2017.22.49.17-00269
Loading

Data & Media loading...

Comment has been disabled for this content
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error